Renal Cancer Clinical Trial
Official title:
Follow-up of Kidney Cancer Patients From the Central European Multicenter Case-Control Study
Background:
In Central Europe, mortality rates for kidney cancers are higher and survival rates are lower
than in the United States and Western Europe overall.
The Central and Eastern European Renal Cancer Case-Control Study (CEERCC), completed in 2002,
offers an opportunity to identify determinants that predict 5-year survival among kidney
cancer patients.
Objectives:
To assess disease recurrence and progression among former participants in the CEERCC.
To investigate the effect of genetics, lifestyle factors, medical conditions, occupation and
diet on the outcome of kidney cancer patients in Europe.
Eligibility:
Former participants or next-of-kin of former participants in the CEERCC study.
Design:
Participants or their next-of-kin are interviewed for 60 minutes and are requested permission
to collect relevant information from their or their family member s hospital and cancer
registry records.
Previously we proposed to conduct a follow-up study of kidney cancer in the high risk region
of Central and Eastern Europe. This study was conducted through the follow-up of a group of
patients with kidney cancer, that were previously enrolled in the study entitled, Occupation,
Genetic Susceptibility Kidney Cancer: Central European Case-Controls Study, PI Dr. Wong-Ho
Chow, OEEB, DCEG, NCI, protocol No 01-C-NO63, a study for which field work and data analyses
of the case control study were completed. We had originally planned to conduct the follow-up
study in seven centers in four countries, including Romania, Poland, Russia, and the Czech
Republic. In each center, cancer-related information was to be extracted from vital
statistics, cancer registry, and/or medical records. For deceased patients, next-of-kin were
to be interviewed using a brief questionnaire.
A pilot study was conducted to determine the feasibility of collecting survival information
including 5-year survival status, date of death, cause of death, and date of last follow-up
if alive from 220 cases across the seven collaborating centers. The feasibility of extracting
additional data including surgical and medical treatment procedures used to treat primary
disease, the recurrence and progression of primary disease was also determined. However,
based on results obtained from the pilot study, we determined that it is feasible to collect
follow-up data from kidney cancer cases from four centers in the Czech Republic and one
center in both Poland and Russia.
Medical records/archives for Romanian cases were located in hospitals that were completely
destroyed during reconstruction therefore, it was impossible to collect any information from
this subset of patients. Exclusion of these records will not affect study power since most of
the cases were from the Czech Republic. The objective of our proposed study remains the
same:( 1) to assess the 5-year survival status of kidney cancer patients in the Central and
Easter European Renal Cell Carcinoma Study; (2) to examine prevalence of recurrent disease
and progression; (3) to investigate additional patient-tumor-and genetic determinant of
5-year survival in cases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03203473 -
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
|
Phase 2 | |
Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 |